CCR6 and neoplasm: Th17 cells recruited via the CCL20-CCR6 axis in the tumor microenvironment (TME) are drivers of worse clinical outcomes (Zhang et al., 2009; Liao et al., 2013; Li et al., 2016; Li et al., 2017) and ICs have been well demonstrated to account for immunosuppressive microenvironment formation that favors anti-tumor immune evasion (Sangro et al., 2021).